Company Expands HYALOFAST Commercial Reach in Asia , the Middle East and Latin America BEDFORD, Mass. --(BUSINESS WIRE)--Dec. 4, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary
Long-Serving Director Steven Wheeler to Retire from Board in February 2019 BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 24, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on
BEDFORD, Mass. --(BUSINESS WIRE)--Oct. 10, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2018 financial results after the close of the market on Wednesday, October 24, 2018 and hold its investor conference call on the same day,
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) (“Anika” or the “Company”), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that
BEDFORD, Mass. --(BUSINESS WIRE)--Sep. 5, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA") technology , today announced that its President and Chief
Solid Top and Bottom Line Performance with 8% Product Revenue Growth and $0.68 Diluted EPS New Leadership Added to Optimize Commercial Reach and Operating Efficiency Multiple Initiatives Ongoing to Gain U.S. Regulatory Approval of CINGAL BEDFORD, Mass. --(BUSINESS WIRE)--Jul.
BEDFORD, Mass. --(BUSINESS WIRE)--Jul. 11, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its second-quarter 2018 financial results after the close of the market on Wednesday, July 25, 2018 and to hold a conference call the next day, Thursday, July
CINGAL 16-02 study did not achieve statistical significance at primary endpoint of 26 weeks in active comparator study; Company committed to working closely with regulators to gain U.S. approval Strong pain reduction and overall symptom relief consistent with statistically significant results of
BEDFORD, Mass. --(BUSINESS WIRE)--May 23, 2018-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics based on its proprietary hyaluronic acid (“HA”) technology , today announced that it will enter into an
